hotspot -WSS

hotspot

author：knowledge 2025-09-30 15:15:09 - browse：8

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Walensky prepares to leave CDC — and Congress — behind

focus

WSS

ChatGPT in medicine: STAT answers readers' burning questions

Apple is now the first public company to be valued at $3 trillion

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Dexcom's push to bring CGM to type 2 diabetes patients

A letter from the executive editor: The 2023 STATUS List

Security flaws in third

focus

hotspot

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Dexcom's push to bring CGM to type 2 diabetes patients

After affirmative action ruling, medical educators look to 'holistic review'

Supreme Court strikes down use of affirmative action

Wildfire smoke exposes gaps in outdoor worker protections

Undocumented workers face uncertainty as immigration law takes effect in Florida

ChatGPT in medicine: STAT answers readers' burning questions

Being 'nonadherent' patient made me a more empathetic doctor

Sports medicine is finally prioritizing gender equality

Heart attack and stroke risk calculators need revising

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Sports medicine is finally prioritizing gender equality

How to save PrEP access — and even expand it

Dexcom's push to bring CGM to type 2 diabetes patients

Affirmative action in medical school literally saved lives

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

focus

focus

leisure time

knowledge